2.50
+0.02(+0.81%)
Currency In USD
| Previous Close | 2.48 |
| Open | 2.5 |
| Day High | 2.52 |
| Day Low | 2.44 |
| 52-Week High | 3.1 |
| 52-Week Low | 0.4 |
| Volume | 755,783 |
| Average Volume | 5.18M |
| Market Cap | 393.86M |
| PE | 5.21 |
| EPS | 0.48 |
| Moving Average 50 Days | 1.94 |
| Moving Average 200 Days | 1.17 |
| Change | 0.02 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) since IPO date, it would be worth $193.8 as of July 06, 2025 at a share price of $2.5. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $304.88 as of July 06, 2025 at a share price of $2.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and cha
CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma
GlobeNewswire Inc.
May 19, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combina
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
May 12, 2025 10:50 AM GMT
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923